The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)
Howard L. McLeod(University of North Carolina at Chapel Hill), Antonius A. Miller(Roswell Park Comprehensive Cancer Center), Deanna L. Kroetz(University of California, San Francisco), Mark J. Ratain(University of Chicago), Robert R. Bies(University at Buffalo, State University of New York), Lionel D. Lewis(Dartmouth College), Chen Jiang(Union Hospital), Kouros Owzar(Duke University), Merrill J. Egorin(Beth Israel Deaconess Medical Center), Svetlana V. Markova(Institute of Biophysics)
Cited by 3
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
|Journal of Clinical Oncology|2011|551